PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
16.39%
Revenue growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.50%. Joel Greenblatt would verify if operating margins keep pace with this top-line surge.
6.16%
Gross profit growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.07%. Joel Greenblatt would check if cost advantages or brand equity drive this surge.
-39.85%
Negative EBIT growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-39.85%
Negative operating income growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
2.92%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.62%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
-2.20%
Negative EPS growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-2.20%
Negative diluted EPS growth while Drug Manufacturers - Specialty & Generic median is 2.67%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
29.60%
Share change of 29.60% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if the modest difference matters long-term.
23.80%
Diluted share change of 23.80% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
-62.19%
Negative OCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
32.43%
FCF growth of 32.43% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-90.89%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-90.89%
Negative 5Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
336.85%
3Y OCF/share growth of 336.85% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
228.97%
Net income/share CAGR of 228.97% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
228.97%
Net income/share CAGR of 228.97% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
879.72%
3Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 4.89%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
539.94%
Equity/share CAGR of 539.94% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
539.94%
5Y equity/share CAGR of 539.94% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
1391.78%
3Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 15.08%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.51%
AR growth of 32.51% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
2.64%
Inventory growth of 2.64% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
63.87%
Asset growth of 63.87% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
33.53%
BV/share growth of 33.53% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-4.80%
Debt is shrinking while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman might see an advantage if growth remains possible.
-65.35%
R&D dropping while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
26.25%
SG&A growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.